DECEMBER 2017
HEMATOLOGY
--- Content provided by FirstRanker.com ---
PAPER-II
Time : 3 hours
Max. Marks :100
Attempt all questions in order.
Each question carries 10 marks.
--- Content provided by FirstRanker.com ---
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
--- Content provided by FirstRanker.com ---
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
- Neutrophil function tests 4+3+3
- Chediak Higashi syndromes 3+4+3
- Granulocyte transfusions 4+3+3
- Management of idiopathic hypereosinophilic syndrome 3+2+3+2
- Role of PDGRFa in hypereosinophilia
- Acquired eosinophilia
- Diagnosis of systemic mastocytosis
- Granules of basophils
- Causes of basophilia in peripheral blood.
--- Content provided by FirstRanker.com ---
- Diagnosis of chronic myelomonocytic leukemia (CMML). 3+4+3
- How does it differ from MDS with excess blasts?
- Management of CMML
- Infections causing monocytosis.
- Histomonophagocytic Syndrome: 2+1+3+4
- What are the causes?
- Criteria for diagnosis
- Langerhan’s cell histiocytosis.
- Chronic lymphocytic leukemia: 4+4+2
- Diagnosis of CLL
- How to distinguish it from monoclonal B lymphocytosis.
- The genetic landscape of CLL and the implications in prognosis.
- Current management of CLL
--- Content provided by FirstRanker.com ---
- Plasma cells: 4+4+2
- What are the imaging techniques for the diagnosis of bone disease in multiple myeloma and their advantages/disadvantages?
- Criteria for the diagnosis of multiple myeloma, smoldering multiple myeloma and MGUS.
- How to differentiate between multiple myeloma and lymphoplasmacytic lymphoma?
--- Content provided by FirstRanker.com ---
- What is hemovigilance? How will you implement this in blood bank? 5+5
- Risk stratification in MDS Treatment options in low risk MDS 5+5
- Acquired causes of thrombocytosis 2+4+4
- JAK 2 pathway and its inhibitors in myeloproliferative neoplasms
- Management of essential thrombocythemia
--- Content provided by FirstRanker.com ---
--- Content provided by FirstRanker.com ---
--- Content provided by FirstRanker.com ---
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
--- Content provided by FirstRanker.com ---
This download link is referred from the post: DNB 2017 Dec Previous Question Papers-(Diplomate of National Board) Under NBE
--- Content provided by FirstRanker.com ---